| Mrs Donna Jaree Brooks, MA LCPC | |
|
3716 W Brighton Ave, Peoria, IL 61615-2938 | |
| (309) 692-7755 | |
| (309) 692-2262 |
| Full Name | Mrs Donna Jaree Brooks |
|---|---|
| Gender | Female |
| Speciality | Counselor |
| Location | 3716 W Brighton Ave, Peoria, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013972082 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (Illinois) | Primary |
| Entity Name | John Day & Associates, Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245454313 PECOS PAC ID: 0446201693 Enrollment ID: O20050927001346 |
News Archive
A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.
GenVec, Inc. today announced a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new agreement, GenVec could receive approximately $13 million over four years to manufacture clinical trial material for up to two lead candidates.
Patients with Parkinson's disease can make rapid responses to avoid adverse stimuli, but cannot speed up their actions to gain a reward, report UK researchers.
News outlets fact-check the bipartisan health care summit and provide analyses of the messaging and poll numbers lawmakers used during the six-hour event.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Donna Jaree Brooks, MA LCPC 3716 W Brighton Ave, Peoria, IL 61615-2938 Ph: (309) 692-7755 | Mrs Donna Jaree Brooks, MA LCPC 3716 W Brighton Ave, Peoria, IL 61615-2938 Ph: (309) 692-7755 |
News Archive
A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.
GenVec, Inc. today announced a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new agreement, GenVec could receive approximately $13 million over four years to manufacture clinical trial material for up to two lead candidates.
Patients with Parkinson's disease can make rapid responses to avoid adverse stimuli, but cannot speed up their actions to gain a reward, report UK researchers.
News outlets fact-check the bipartisan health care summit and provide analyses of the messaging and poll numbers lawmakers used during the six-hour event.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
› Verified 9 days ago
Ms. Debra Fay Disney, LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 7617 N Villa Wood Ln, Peoria, IL 61614 Phone: 309-693-8200 | |
Mrs. Linda L Zears, MS LCPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3716 W Brighton Ave, Peoria, IL 61615 Phone: 309-692-7755 Fax: 309-692-2262 | |
Mrs. Tamara Marie Lott, LCPC, CRC Counselor Medicare: Medicare Enrolled Practice Location: 515 Ne Glen Oak Ave Ste 101, Osf Saint Francis Medical Center, Peoria, IL 61603 Phone: 309-655-7795 Fax: 309-655-4609 | |
Dr. Michael S Shear, PSY.D. Counselor Medicare: Not Enrolled in Medicare Practice Location: 456 Fulton St, Suite 101, Peoria, IL 61602 Phone: 309-673-9385 Fax: 309-673-9446 | |
Mrs. Sandra Susan Cross, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 2522 W Stronehenge Ct, Peoria, IL 61615 Phone: 309-264-9517 | |
Amy M. Cundiff, MA, NCC, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 4806 N Sheridan Rd, Peoria, IL 61614 Phone: 309-682-6258 Fax: 309-682-6472 |